BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...

Leukemia symptoms include fatigue, weakness, chest pain, shortness of breath, bleeding, bruising, and increased infection risk due to altered blood cell counts. Recent leukemia treatment advancements ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...

BEXAR COUNTY, Texas – These days, rising costs are not only a reality for everyday necessities. The cost of health care, including the life-saving treatment for various blood cancers, has also been on ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...